Cat.No：GM-87820AB
Product：Anti-HER3-DXD(Dar8)[Patritumab deruxtecan]
Cat.No：GM-87820AB
Product：Anti-HER3-DXD(Dar8)[Patritumab deruxtecan]
GM-87820AB-100 100μg
GM-87820AB-1mg 1mg
Expression System | CHO |
Purity | > 95% as determined by SDS-PAGE |
Aggregation | < 5% as determined by SEC-HPLC |
Drug-to-Antibody Ratio (DAR) | 8.0 |
Endotoxin | <1EU/mg |
Sterility | 0.22 μm Filtered |
Target | HER3 |
Clone | Patritumab deruxtecan |
Alternative Names | ERBB3 |
Source/Isotype | Monoclonal Human IgG1(KDEL), kappa |
Application | Positive control of Cytotoxicity Assay |
Description | Patritumab deruxtecan is an innovative antibody-drug conjugate (ADC) that specifically targets HER3 (human epidermal growth factor receptor 3, ErbB3). Patritumab deruxtecan employs a monoclonal antibody against HER3 to deliver the cytotoxic drug deruxtecan, a topoisomerase I inhibitor, directly to tumor cells. The antibody component specifically binds to HER3, and the drug is released inside the tumor cells, inducing DNA damage and cell death, thereby enhancing the antitumor effect. Additionally, due to the targeted delivery characteristic of ADCs, damage to normal cells is reduced, improving the safety profile of the treatment. |
Formulation | 10 mM NaAc-HAc, pH5.0 |
Cat.No：GM-87820AB
Product：Anti-HER3-DXD(Dar8)[Patritumab deruxtecan]
GM-87820AB-100 100μg
GM-87820AB-1mg 1mg
Expression System | CHO |
Purity | > 95% as determined by SDS-PAGE |
Aggregation | < 5% as determined by SEC-HPLC |
Drug-to-Antibody Ratio (DAR) | 8.0 |
Endotoxin | <1EU/mg |
Sterility | 0.22 μm Filtered |
Target | HER3 |
Clone | Patritumab deruxtecan |
Alternative Names | ERBB3 |
Source/Isotype | Monoclonal Human IgG1(KDEL), kappa |
Application | Positive control of Cytotoxicity Assay |
Description | Patritumab deruxtecan is an innovative antibody-drug conjugate (ADC) that specifically targets HER3 (human epidermal growth factor receptor 3, ErbB3). Patritumab deruxtecan employs a monoclonal antibody against HER3 to deliver the cytotoxic drug deruxtecan, a topoisomerase I inhibitor, directly to tumor cells. The antibody component specifically binds to HER3, and the drug is released inside the tumor cells, inducing DNA damage and cell death, thereby enhancing the antitumor effect. Additionally, due to the targeted delivery characteristic of ADCs, damage to normal cells is reduced, improving the safety profile of the treatment. |
Formulation | 10 mM NaAc-HAc, pH5.0 |
